Literature DB >> 16122477

Proper treatment selection may improve survival in patients with clinical early-stage nonsmall cell lung cancer.

Ozcan Birim1, A Pieter Kappetein, Tom Goorden, Rob J van Klaveren, Ad J J C Bogers.   

Abstract

BACKGROUND: In patients with early-stage nonsmall cell lung cancer treatment selection is rarely assessed. Many surgical papers report only the outcome of patients who underwent surgery although selection may influence the outcome. In this report, treatment selection and the outcome of both surgically and nonsurgically treated patients is evaluated.
METHODS: Three hundred sixty patients (269 surgically treated and 91 nonsurgically treated) with clinical stage I and II were included. Risk factors were scaled according to the Charlson comorbidity index (CCI). Hospital morbidity and long-term survival were evaluated.
RESULTS: Mean age was 64 years for the surgical and 74 for the nonsurgical patients. Mean CCI score was 1.3 and 2.4, and 5-year survival was 47% and 3%, respectively. Male sex, pneumonectomy, and CCI score of 3 or more were predictive for major postoperative complications. For the nonsurgical patients receiving radiotherapy, the 2-year survival was 40%; for the patients receiving no radiotherapy, 2-year survival was 5%. Male sex, age, treatment, and clinical stage were prognostic for survival. Patients with a CCI score of 3 or more showed a better survival after surgery than after radiotherapy. Patients with a CCI score of 3 or more who were surgically treated had a higher prevalence of forced expiratory volume in 1 second of 70% or more compared with the patients receiving radiotherapy.
CONCLUSIONS: Patients with a CCI score of 3 or more have an increased risk of major postoperative complications. Nevertheless, patients with a CCI score of 3 or more show a better survival after surgery than after radiotherapy. For patients with significant comorbidity but with sufficient pulmonary reserve, surgery offers the best outcome. For patients with a high CCI score and insufficient pulmonary reserve or for those who refuse surgery curative, radiotherapy is a good alternative.

Entities:  

Mesh:

Year:  2005        PMID: 16122477     DOI: 10.1016/j.athoracsur.2005.03.072

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

1.  Improving lung cancer outcomes by improving the quality of surgical care.

Authors:  Raymond U Osarogiagbon; Thomas A D'Amico
Journal:  Transl Lung Cancer Res       Date:  2015-08

2.  Risk factors for 30-day mortality after resection of lung cancer and prediction of their magnitude.

Authors:  Trond-Eirik Strand; Hans Rostad; Ronald A M Damhuis; Jarle Norstein
Journal:  Thorax       Date:  2007-06-15       Impact factor: 9.139

3.  Is the initial feasibility of lobectomy for stage I non-small cell lung cancer in severe heterogeneous emphysema justified by long-term survival?

Authors:  Antonio E Martin-Ucar; Khaleel R Fareed; Apostolos Nakas; Paul Vaughan; John G Edwards; David A Waller
Journal:  Thorax       Date:  2007-02-08       Impact factor: 9.139

4.  Treatment and survival differences in older Medicare patients with lung cancer as compared with those who are dually eligible for Medicare and Medicaid.

Authors:  Cathy J Bradley; Bassam Dahman; Charles W Given
Journal:  J Clin Oncol       Date:  2008-09-15       Impact factor: 44.544

5.  Comorbidity as an independent prognostic factor in elderly patients with peripheral T-cell lymphoma.

Authors:  Haifeng Zhao; Tengteng Wang; Yafei Wang; Yong Yu; Xiaofan Wang; Zhigang Zhao; Hongliang Yang; Bei Yan; Xiaoxiong Wu; Wanming Da; Yizhuo Zhang
Journal:  Onco Targets Ther       Date:  2016-03-24       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.